Sep 14, 2010

Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges

Molecular Pharmaceutics
Svetlana Verenich, Phillip M Gerk

Abstract

2-Methoxyestradiol (2MeO-E2) is an endogenous metabolite of estrogen which was initially considered to be inactive. During the last few decades it has been shown that 2MeO-E2 is a promising anticancer drug. In vitro experiments have demonstrated that it has several anticancer activities, and potential to alleviate hypertension, glomerulosclerosis, hypercholesterolemia, and other disorders. However, due to its low solubility and extensive glucuronidation, to achieve effective concentrations large doses of 2MeO-E2 would be required. Clinical studies reflected very high inter- and intrapatient variability and oral bioavailability of 1 to 2%. Thus, this review paper highlights the origin of this compound, its therapeutic promises, and possible mechanisms of action. It also discusses the pharmacokinetic properties of 2MeO-E2 as well as current developments to overcome low drug solubility and its extensive first pass metabolism.

Mentioned in this Paper

Metabolic Process, Cellular
Antineoplastic Agents
Apoptosis, Intrinsic Pathway
Diabetic Nephropathy
Panzem
Estradiol, (16 alpha,17 beta)-Isomer
Hypercholesterolemia
Glomerulosclerosis (Disorder)
Cell Proliferation
Metabolic Pathway

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.